login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
All US stocks
All Canadian stocks
All European stocks
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Account
Disclaimer
Affiliate
Contact
Privacy
ACLARIS THERAPEUTICS INC (ACRS) Stock News
NASDAQ:ACRS -
US00461U1051
-
Common Stock
2.13
USD
+0.05 (+2.65%)
Last: 9/9/2025, 8:00:00 PM
2.13
USD
0 (0%)
Pre-Market:
9/10/2025, 4:56:09 AM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
ACRS Latest News, Press Relases and Analysis
All
Press Releases
a day ago - By: Aclaris Therapeutics, Inc.
Aclaris Therapeutics Announces Late-Breaking Abstract and Oral Presentation On ATI-2138 Phase 2a Results at the 2025 European Academy of Dermatology and Venereology (EADV) Congress
14 days ago - By: Aclaris Therapeutics, Inc.
Aclaris Therapeutics to Participate in Two September Healthcare Conferences
a month ago - By: Zacks Investment Research
- Mentions:
NTRB
Aclaris Therapeutics (ACRS) Reports Q2 Loss, Beats Revenue Estimates
a month ago - By: Zacks Investment Research
- Mentions:
HROW
Harrow (HROW) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
a month ago - By: Benzinga
- Mentions:
SPY
LOGI
MSFT
RCKY
...
Stock Market Today: US Future Edge Higher Ahead Of FOMC Decision—Meta, Microsoft Earnings In Focus
a month ago - By: Aclaris Therapeutics, Inc.
Aclaris Therapeutics Announces Leadership Transition
9 months ago - By: Benzinga
- Mentions:
PCH
WY
GCMG
This Weyerhaeuser Analyst Turns Bullish; Here Are Top 4 Upgrades For Monday
a month ago - By: Aclaris Therapeutics, Inc.
Aclaris Therapeutics Announces Positive Top-Line Results from Open-Label Phase 2a Trial of ATI-2138, a Potent and Selective Investigational Inhibitor of ITK and JAK3; Trial Achieves Primary and Key Secondary Endpoints
2 months ago - By: Aclaris Therapeutics, Inc.
Aclaris Therapeutics Added to the Russell 2000® and Russell 3000® Indexes
10 months ago - By: Aclaris Therapeutics, Inc.
Aclaris Therapeutics Announces $80 Million Private Placement
3 months ago - By: Aclaris Therapeutics, Inc.
Aclaris Therapeutics to Participate in the H.C. Wainwright Inflammation & Immunology Virtual Conference
3 months ago - By: Aclaris Therapeutics, Inc.
Aclaris Therapeutics Initiates Phase 1a/1b Program for its Novel Bispecific Antibody ATI-052
3 months ago - By: Aclaris Therapeutics, Inc.
Aclaris Therapeutics to Participate in Two June Healthcare Conferences
4 months ago - By: Aclaris Therapeutics, Inc.
Aclaris Therapeutics to Participate in the HC Wainwright “HCW@Home” Series
4 months ago - By: Zacks Investment Research
- Mentions:
PSTV
Aclaris Therapeutics (ACRS) Reports Q1 Loss, Misses Revenue Estimates
4 months ago - By: Aclaris Therapeutics, Inc.
Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
4 months ago - By: Aclaris Therapeutics, Inc.
Aclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical Officer
5 months ago - By: Aclaris Therapeutics, Inc.
Aclaris Therapeutics Secures U.S. Food and Drug Administration IND Clearance for ATI-052, Enabling Advancement of its Novel Bispecific Anti-TSLP/IL-4R Investigational Antibody
6 months ago - By: Aclaris Therapeutics, Inc.
Aclaris Therapeutics to Participate in Two March Healthcare Conferences
6 months ago - By: Aclaris Therapeutics, Inc.
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update
7 months ago - By: Aclaris Therapeutics, Inc.
New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3
7 months ago - By: Aclaris Therapeutics, Inc.
Aclaris Therapeutics Announces Formation of New Scientific Advisory Board
8 months ago - By: Aclaris Therapeutics, Inc.
Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
9 months ago - By: Yahoo Finance
- Mentions:
RJF
WY
PCH
GCMG
Pony AI, Thermo Fisher initiated: Wall Street's top analyst calls
9 months ago - By: Aclaris Therapeutics, Inc.
Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
10 months ago - By: Aclaris Therapeutics, Inc.
Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference
10 months ago - By: Biosion, Inc.
Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets
10 months ago - By: Aclaris Therapeutics, Inc.
Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline
Please enable JavaScript to continue using this application.